Pharmaceuticals

Jefferies & Co. has a Buy rating on shares of Digital Realty Trust, Inc. (NYSE: DLR). In the research report sent to investors, Jefferies writes, "We are bullish on the data center real estate market, which is poised to experience positive demand/supply fundamentals for the next five years, in...

3M Company (MMM) has acquired a Port St. Lucie, FL-based manufacturer of structural honeycomb core and fiber-reinforced foam core materials, Nida-Core Corp. The company did not reveal the terms of the deal. Nida-Core offers a range of high-strength, low-weight, engineered materials. Through its...

3M Company (MMM) has acquired a Port St. Lucie, FL-based manufacturer of structural honeycomb core and fiber-reinforced foam core materials, Nida-Core Corp. The company did not reveal the terms of the deal. Nida-Core offers a range of high-strength, low-weight, engineered materials. Through its...

Shares of Amarin Corporation plc (Nasdaq: AMRN) are trading down 7.7% at $7.69 per share during the Tuesday afternoon trading session. The day's range for shares of Amarin Corporation plc has been between $7.52 and $8.18 per share. The average price target of analysts who cover Amarin Corporation...

Wedbush Equity Research has an $8.50 price target on shares of CARDIOME PHARMA CORP (NASDAQ: CRME) and an Outperform rating on shares. In the research note, Wedbush writes, "While last week's announcement provided some positive momentum for CRME, we believe that investors will be most receptive to...

We remain Neutral on Bristol-Myers Squibb Company (BMY) with a price target of $28.00. Bristol-Myers, headquartered in New York, is a major producer and distributor of pharmaceuticals and other healthcare-related products. The company manufactures and sells branded pharmaceutical drugs such as...

We remain Neutral on Bristol-Myers Squibb Company (BMY) with a price target of $28.00. Bristol-Myers, headquartered in New York, is a major producer and distributor of pharmaceuticals and other healthcare-related products. The company manufactures and sells branded pharmaceutical drugs such as...

Shares of Auxilium Pharmaceuticals (NASDAQ: AUXL) are higher on the session by 0.70%, trading at $21.61. Overall call volume is now running at 2.93x the daily average, with 66% of all calls traded being purchases on the offer. 1,410 contracts have traded on the session so far. Auxilium...

Kevin Matras shows the right way to find great growth stocks at an excellent value. Highlighted stocks include DX, HITK, OI, TECD and WRLD. DYNEX CAP INC (DX): Free Stock Analysis Report HI TECH PHARMA (HITK): Free Stock Analysis Report OWENS-ILLINOIS (OI): Free Stock Analysis Report TECH DATA CORP...

Shares of Salix Pharmaceuticals (NASDAQ: SLXP) are lower on the session by 1.83%, currently trading at $47.15. The stock has been moving largely higher over the past two months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the name today...

Pfizer Inc. (PFE) recently completed its acquisition of Synbiotics Corp. for an undisclosed amount. With the closing of this deal, Synbiotics will become a part of Pfizer's Animal Health unit. Synbiotics specializes in the manufacturing of immunodiagnostic tests for animals. The acquisition...

Deutsche Bank has published a research report on Inspire Pharmaceuticals (NASDAQ: ISPH) after downgrading the company to Hold from Buy yesterday. In the report, Deutsche Bank writes "Early Monday, we downgraded Inspire shares to Hold, following the announcement of negative results for TIGER-2, the...

Pfizer Inc. (PFE) recently completed its acquisition of Synbiotics Corp. for an undisclosed amount. With the closing of this deal, Synbiotics will become a part of Pfizer's Animal Health unit. Synbiotics specializes in the manufacturing of immunodiagnostic tests for animals. The acquisition...

Goldman Sachs has published a research report on Johnson & Johnson (NYSE: JNJ) and has lowered estimates on the company as a result of slow recovery on the company's MD&D and OTC businesses. In the report, Goldman Sachs writes "In 2010, JNJ's MD&D has slowed considerably due to the...

ULURU Inc. (NYSE: ULU) today announced it has entered into a definitive agreement to sell 5,000,000 shares of its common stock at a price per share of $0.10 pursuant to a registered direct offering to an institutional investor, resulting in gross proceeds of approximately $500,000.